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Abstract The 42/43-residue amyloid L-peptide (AL) is widely
believed to play a major role in Alzheimer’s disease. The present
study shows that the rat brain contains a carboxypeptidase that
efficiently deletes three amino acids from AL1^43. The
carboxypeptidase activity in the brain was completely inhibited
by 1 mM phenylmethylsulfonyl fluoride, suggesting the protease
is a serine carboxypeptidase. The carboxy-terminal truncation of
AL1^43 was moderately inhibited by carbobenzoxy-Leu-leucinal,
carbobenzoxy-Leu-Leu-leucinal, and carbobenzoxy-Leu-Leu-
norvalinal, and weakly by antipain. The present data suggest
that the serine carboxypeptidase contributes to the generation of
short-tailed AL peptides and is important in the intracellular
clearance of AL1^42/43 in brains.
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1. Introduction
Amyloid L-peptide (AL) is a 4-kDa peptide deposited as
amyloid in the brains of all patients with Alzheimer’s disease
(AD) [1^3]. AL is a 39^43-residue heterogeneous peptide de-
rived from proteolytic processing of the L-amyloid precursor
protein (APP) by L-secretase, the protease that cleaves at the
amino-terminus, and Q-secretase, the protease that cleaves at
the carboxy-terminus [3]. AL1^40 is the major species found in
cerebrospinal £uid [4] and approximately 90% of AL peptides
secreted from cultured cells terminate at residue 40 [5,6].
However, all three early-onset familial Alzheimer’s disease
(FAD) genes identi¢ed to date have been shown to cause an
enhanced production of AL ending at residues 42 or 43 [7^9].
Furthermore, the long-tailed AL is the major and early com-
ponent within senile plaques of patients with sporadic AD,
Down’s syndrome, as well as FAD [10^13]. Therefore, AL1^
42/43 appears to play a major role in FAD and AD. Even
though the mechanism by which neurons are selectively killed
by AL1^42 is not determined, the intracellular accumulation
of AL1^42 is suspected to be very dangerous for neurons,
because ERAB, a newly found protein locating the endoplas-
mic reticulum (ER) of neural cells, relocates to the cell mem-
branes after binding to AL1^42 and causes apoptosis [14].
Recently, it was demonstrated that AL1^42 was generated
within the ER or the Golgi and AL1^42 but less AL1^40
occurred in cultured cells transfected with APP [15]. In order
to understand the mechanism to produce the carboxy-terminal
heterogeneity of AL peptides several kinds of protease inhib-
itors have been examined and it was found that the secretion
of AL1^40 into the medium from several cultured cells was
reduced accompanying a slight increase of AL1^42 after treat-
ment with peptide aldehydes such as MDL 28170, calpain
inhibitor I, and carbobenzoxy-Leu-Leu-leucinal [16^18].
Based on these ¢ndings two types of Q-secretases (endopepti-
dases) have been postulated; one cleaves after amino acid 40
of AL and is sensitive to peptide aldehyde, and the other
cleaves after amino acid 42 and is resistant to the inhibitor
[17,18].
Since the binding of AL1^42 to ERAB protein in neural
cells leads to apoptosis [14], the degradation of AL1^42/43 is
supposed to be important to prevent neural dysfunction. In
the previous paper I have reported that cathepsin D is the
major endopeptidase that hydrolyzes AL in the middle of
the sequence to eliminate the AL peptides [19]. However, to
decrease intracellular levels of AL1^42/43, there must be a
carboxypeptidase that is able to produce short-tailed AL
from AL1^42/43, because cathepsin D hydrolyzes the long-
tailed AL less e⁄ciently than AL1^40 [20]. The present work
shows that the rat brain contains the carboxypeptidase which
successively removes three amino acids from AL1^43 produc-
ing AL1^40. In addition it was found that the carboxypepti-
dase activity was inhibited by peptide aldehyde protease in-
hibitors. The results suggest that the carboxypeptidase
contributes to the generation of AL1^40 from AL1^42/43
and that the peptide aldehyde protease inhibitors may de-
crease the secretion of AL1^40 by their inhibition against
the carboxypeptidase.
2. Materials and methods
AL1^40 and AL1^43 were obtained from Bachem. Phenylmethyl-
sulfonyl £uoride (PMSF) and p-chloromercuribenzoic acid (PCMB)
was purchased from Sigma. Carbobenzoxy-L-Leu-L-leucinal (Z-Leu-
LeuH), carbobenzoxy-L-Leu-L-Leu-L-leucinal (Z-Leu-Leu-LeuH), car-
bobenzoxy-L-Leu-L-Leu-L-norvalinal (Z-Leu-Leu-NvaH), biotinyl-L-
Asp-L-Glu-L-Val-L-aspart-1-al (biotin-Asp-Glu-Val-AspH), leupeptin,
antipain, and pepstatin A were obtained from Peptide Institute, Inc.,
Osaka, Japan. Rat brain was homogenized with 5 volumes of 0.2 M
acetate bu¡er, pH 5.2, containing 1 WM pepstatin A using a Polytron
homogenizer at 0‡C and centrifuged at 25 000Ug for 60 min at 4‡C.
The supernatant fraction was dialyzed against acetate bu¡er (0.05 M,
pH 5.2) and centrifuged to remove debris before use for enzyme assay.
The carboxypeptidase activity was assayed by analyzing released ami-
no acids after incubating the mixture of 20 Wl of brain extract in
acetate bu¡er (0.05 M, pH 5.2) and 20 Wl of AL peptide (50 WM) at
37‡C. Peptide aldehyde protease inhibitors were dissolved as stock
solution of 10 mM just before use. Z-Leu-Leu-H, Z-Leu-Leu-Leu-
H, Z-Leu-Leu-NvaH, and biotin-Asp-Glu-Val-AspH were dissolved
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in dimethyl sulfoxide and other peptide aldehyde inhibitors were in
distilled water. In order to assay the e¡ects of protease inhibitors 0.4
Wl of inhibitors were added to 40 Wl of the incubation mixture. En-
zyme assay was performed three times independently. 10-Wl aliquots
of incubation mixture were used to analyze released amino acids using
a method reported by Chang et al. [21].
3. Results and discussion
In the previous work it was shown that cathepsin D is the
major protease in the rat brain that is able to hydrolyze AL
peptides; inhibitor assay has shown that other lysosomal pro-
teases did not degrade the peptides [19]. However, there is no
reason to rule out the possibility that carboxy-terminus of AL
peptides is deleted by lysosomal or other exopeptidase(s),
since it has been shown that AL1^42 in media is internalized
by cultured cells and truncated at the amino-terminus [22]. In
order to test this possibility, the cleavage of carboxy-terminal
amino acids from AL1^43 were assayed using rat brain ex-
tract. Since in the preliminary experiments it has been shown
that carboxypeptidase activity of the rat brain was highest at
pH 5.0^5.5, the enzyme activity was assayed in 0.05 M acetate
bu¡er (pH 5.2) in the following experiments. When 1 nmol of
AL1^43 was incubated with the rat brain extract, 0.29 nmol of
threonine, 0.29 nmol of alanine, 0.26 nmol of isoleucine, and
0.13 nmol of valine were liberated in 2 h under the experi-
mental conditions (Fig. 1). Release of other amino acids was
negligible. The release of threonine from AL1^43 was two
times faster than that of valine (Val-40 plus Val-39) from
AL1^40. Since the release of Thr-43, Ala-42 and Ile-41 is
faster than that of Val-40 plus Val-39, it would be reasonable
to suppose that AL1^40 and AL1^39 are produced from AL1^
42/43 by the action of carboxypeptidase and partly secreted
from cells before further degradation by the carboxypeptidase
and lysosomal endopeptidases. Fig. 2 shows that 1 mM
PMSF completely inhibits the carboxypeptidase, while the in-
hibition by 2 mM EDTA or 1 mM PCMB was incomplete,
suggesting the enzyme belongs to serine carboxypeptidase.
Recently, peptide aldehyde protease inhibitors have been
shown to a¡ect di¡erently on the generation of AL1^42 and
AL1^40. Klafki et al. examined the secretion of AL1^40 and
AL1^42 by cultured cells expressing APP with the Swedish
double mutation and found the reduction of AL1^40 after
treatment with calpain inhibitor I (N-acetyl-Leu-Leu-norleu-
cinal) or Z-Leu-Leu-LeuH accompanying a slight increase of
AL1^42 released into the medium [18]. Citron et al. also ob-
served a peptide aldehyde with calpain inhibitor activity,
MDL 28170 (carbobenzoxy-Val-phenylalaninal), reduces the
amount of secreted AL40 peptide into media from cultured
cells [17]. Both observations may suggest that two kinds of Q-
secretases are present and peptide aldehydes reduce the secre-
tion of AL1^40 by its inhibition against Q-secretase which is
speci¢c for the cleavage after residue 40, even though Q-secre-
tase with such substrate speci¢city is yet to been identi¢ed. If
the carboxypeptidase is engaged in the generation of AL1^40,
it is expected that the enzyme is inhibited by peptide aldehyde
protease inhibitors. Therefore, e¡ects of peptide aldehydes on
the carboxy-terminal cleavage of AL1^43 by rat brain extract
were investigated (Fig. 3A). When 100 WM inhibitors were
used, Z-Leu-LeuH, Z-Leu-Leu-LeuH, Z-Leu-Leu-NvaH, bio-
tinyl-Asp-Glu-Val-AspH, and antipain inhibited the carboxy-
peptidase activity by 66%, 76%, 50%, 17%, and 7%, respec-
tively. IC50 of Z-Leu-Leu-LeuH for the carboxypeptidase was
approximately 60 WM (Fig. 3B). The data suggest that the
carboxypeptidase is an important factor that plays a role in
controlling the levels of AL1^40 and AL1^42/43 and that the
inhibition of the enzyme by peptide aldehydes would lead to
reduced secretion of AL1^40 from cultured cells accompany-
ing increased production of AL1^42/43.
The brain carboxypeptidase is similar to cathepsin A (lyso-
somal serine carboxypeptidase, EC 3.4.16.1) in the following
characteristics : cathepsin A has optimal activity at pH 4.5^
6.0, has wide substrate speci¢city, and has been found in
human brain [23]. However, sensitivity to antipain is di¡erent;
IC50 of antipain for cathepsin A is about 2 WM [24], while
only 7% of the brain carboxypeptidase activity was inhibited
by the inhibitor at 100 WM. The puri¢cation of the carboxy-
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Fig. 1. Carboxy-terminal truncation of AL1^43 and AL1^40 by rat
brain extract. Released amino acids were assayed after AL peptides
(1 nmol) were incubated with rat brain extract for 2 h under the
conditions described in Section 2. Data are means þ S.E. of three in-
dependent experiments.
Fig. 2. Inhibition of carboxy-terminal truncation by PMSF. AL1^43
(1 nmol) was incubated with rat brain extract for 2 h in the pres-
ence or absence (control) of protease inhibitors and subsequently re-
leased Ile-41 was assayed. Data are means þ S.E. of three independ-
ent experiments.
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peptidase is under way. It is surprising that AL1^42/43 is more
sensitive to the brain carboxypeptidase than AL1^40, since
AL1^42/43 is more aggregatable and more resistant to endo-
somal/lysosomal endopeptidases than AL1^40 [20]. Since the
long-tailed AL peptides are very cytotoxic for neural cells [14]
and the intracellular clearance of AL peptides is supposed to
be carried out mostly in endosomes/lysosomes, the carboxy-
terminal truncation of AL1^42/43 by the serine carboxypepti-
dase would be essential to prevent neural dysfunction.
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Fig. 3. Inhibition by peptide aldehydes. Release of Ile-41 from AL1^
43 after 2-h incubation of AL1^43 with brain extract in the presence
or absence (control) of peptide aldehyde. A: Inhibition by 100 WM
peptide aldehyde. Data are means þ S.E. of three independent ex-
periments. B: Dose dependence of inhibition by Z-Leu-Leu-Leu-H.
Data are means of three independent experiments.
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